Our sister site, Drug Delivery Business News, reports today that the company paired Omnipod 5 with the Abbott FreeStyle Libre 2 Plus CGM. Compatibility in the U.S. comes about eight months after the company integrated Omnipod 5 with Libre 2 Plus in Europe.
Insulet’s Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January 2022. It features SmartAdjust technology that predicts where glucose will be 60 minutes into the future every five minutes. Omnipod 5 then increases, decreases, or pauses insulin delivery based on the user’s desired and customized glucose target.
Abbott modified its original FreeStyle Libre 2 for the purpose of integration with automated insulin delivery systems. It labeled it the first and only CGM in the U.S. worn for 15 days for adults and children. The FDA cleared the updated Abbott CGM for use with automated insulin delivery in March 2023.
Get the full story at our sister site, Drug Delivery Business News.
